Looking at eye artery narrowing in advanced dry age-related macular degeneration
Studies whether a narrowed eye artery relates to geographic atrophy in macular degeneration.
Plain-language title generated from the registry record
Registry title: Noninvasive Imaging Biomarkers of Treatable Macrovascular Disease in Age-related Macular Degeneration.
Key facts
- Where
- Cleveland, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 80 years old?
Source: NCT07798323, who can take part
Where in United States
- Cleveland ClinicCleveland, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Scott Raymond
- Trial code
- NCT07798323
- Record updated
- 3 September 2026
- Original description
The purpose of this prospective study is to investigate whether ophthalmic artery stenosis (narrowing of the ophthalmic artery) contributes to the development and progression of geographic atrophy (GA), an advanced form of dry age-related macular degeneration (AMD).Read full original descriptionShow less
Noninvasive Imaging Biomarkers of Treatable Macrovascular Disease in Age-related Macular Degeneration.
The purpose of this prospective study is to investigate whether ophthalmic artery stenosis (narrowing of the ophthalmic artery) contributes to the development and progression of geographic atrophy (GA), an advanced form of dry age-related macular degeneration (AMD).
Inclusion: 50-80 years of age; All genders; Asymmetric dry AMD with geographic atrophy in at least one eye and reduced disease severity in the other eye according to International Classification of Disease (ICD) codes; Treated at the Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio.
Exclusion: Other concurrent retinal diseases; Vitreoretinal surgery; Allergy to iodinated contrast agents; Chronic kidney disease with eGFR < 60; Poor image quality that limits quantification; GA extending beyond the borders of the SDOCT field of view; Bilateral symmetric geographic atrophy; Diagnosis of wet AMD; Any retinal fluid at baseline.